PLX109006

GSE55005: mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer

• Organsim human
• Type RNASEQ
• Target gene
• Project ARCHS4

The intention was to detect genes that are determining trastuzumab efficiency in HER2-positive breast cancer cell lines with different resistance phenotypes.; While BT474 should be sensitive to the drug treatment, HCC1954 is expected to be resistant due to a PI3K mutation.; The cell line BTR50 has been derived from BT474 and was cultured to be resistant as well.; Based on RNA-Seq data, we performed differential expression analyses on these breast cancer cell lines with and without trastuzumab treatment.; In detail, five separate tests were performed, namely resistant cells vs. wild type, i.e. HCC1954 and BTR50 vs. BT474, respectively, and untreated vs. drug treated cells.; The significant genes of the first two tests should contribute to resistance.; The significant genes of the test BT474 vs. its drug treated version should contribute to the trastuzumab effect.; To exclude false positives from the combined gene set (#64), we removed ten genes that were also significant in the test BTR50 vs. its drug treated version.; This way we ended up with 54 genes that are very likely to determine trastuzumab efficiency in HER2-positive breast cancer cell lines. SOURCE: Silvia von der Heyde (silvia.heyde@gmail.com) - University Medical Center Göttingen